CardiacSense Ltd. v. Casio Computer Co. — Dismissed With Prejudice in 46 Days
CardiacSense Ltd., an Israeli wearable health-monitoring company, brought a patent infringement action against Casio Computer Co. in New Jersey District Court, asserting US7980998B2 against the G-SHOCK GBDH2000 multi-sport GPS watch line. The case closed in just 46 days after the parties jointly stipulated to dismissal with prejudice, with each side bearing its own costs.
A rapid resolution: wearable biosensor patent settled before substantive litigation began
On 4 September 2025, CardiacSense Ltd. filed a patent infringement complaint in the United States District Court for the District of New Jersey against Casio Computer Co., Ltd. The suit centred on US7980998B2, a patent directed to wearable multi-sensor health monitoring technology, asserted against Casio’s G-SHOCK GBDH2000 series — a line of multi-sport GPS watches incorporating biosensing capabilities including the GBDH2000-1A, GBDH2000-1A9, and GBDH2000-2 variants.
The case resolved in 46 days. On 20 October 2025, the parties filed a joint stipulation of dismissal with prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii), stating they had ‘reached resolution of this matter.’ Each party agreed to bear its own costs, expenses, and attorneys’ fees. Dismissal with prejudice means CardiacSense cannot refile the same claims against Casio on this patent, and the resolution is final.
A 46-day resolution is notably swift for patent litigation and strongly suggests a pre-litigation or very early-stage settlement was reached, likely before any substantive motions or discovery were filed. The public record does not disclose financial terms, licensing arrangements, or other conditions of the resolution. The mutual cost-bearing provision is consistent with a negotiated settlement rather than a capitulation by either side, though the precise commercial terms remain unknown.
Filing to Dismissed with Prejudice in 46 days
46 days — well under the median district court patent case duration of 2+ years
Dismissed with prejudice: what the joint stipulation means for both parties
FRCP 41(a)(1)(A)(ii): joint stipulation, binding and final
Under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), both parties signed a joint stipulation of dismissal — no court order was required. Dismissal ‘with prejudice’ is the operative phrase: it operates as a final adjudication on the merits, barring CardiacSense from refiling the same infringement claims against Casio under US7980998B2. This is the cleanest form of closure available in federal patent litigation.
Final, no refiling permittedCardiacSense: claims extinguished — resolution suggests value extracted
By agreeing to dismissal with prejudice, CardiacSense permanently waived the right to pursue these specific claims against Casio on US7980998B2. However, the 46-day timeline and joint nature of the stipulation are consistent with a negotiated settlement — potentially including a licence, royalty arrangement, or lump-sum payment — rather than a unilateral abandonment. The public record does not confirm any financial terms.
Claims extinguished; terms undisclosedCasio: litigation risk cleared; G-SHOCK line protected from this action
Casio secured a permanent bar against CardiacSense reasserting US7980998B2 infringement claims for the G-SHOCK GBDH2000 product line in this action. Defendant was represented by Sills Cummis & Gross PC. The mutual cost-bearing clause suggests Casio did not obtain a fee award, which is consistent with an arms-length settlement rather than a finding of exceptional case conduct. Casio’s broader freedom to operate on this patent may depend on any licence terms agreed privately.
Re-suit barred; IP terms privateEarly resolution limits precedent but signals active enforcement of wearable biosensor IP
Because the case resolved before any claim construction, Markman hearing, or validity ruling, US7980998B2 remains untested by this court. Competitors in the wearable multi-sport GPS watch segment — particularly those incorporating optical biosensors or multi-parameter health tracking — should note that CardiacSense appears willing to assert this patent commercially. The absence of a court ruling on validity means the patent’s enforceability scope is unresolved from a public-record standpoint.
Patent validity unresolved by courtFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | CARDIACSENSE LTD | Company | Wearable health-monitoring technology company — holder of US7980998B2Search in Eureka ↗ |
| Defendant | CASIO COMPUTER COMPANY, LTD | Company | Casio Computer Co., Ltd. — Japanese consumer electronics and watch manufacturerSearch in Eureka ↗ |
| Defendant counsel | Katherine Marguerite Leid | Attorney | Counsel for CASIO COMPUTER COMPANY, LTDSearch in Eureka ↗ |
| Defendant law firm | Sills Cummis & Gross PC | Law Firm | Representing CASIO COMPUTER COMPANY, LTDSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The joint stipulation states the parties ‘have reached resolution of this matter’ — language that is deliberately non-specific but unambiguous in effect. Dismissal with prejudice under FRCP 41(a)(1)(A)(ii) forecloses any future infringement action by CardiacSense against Casio on these claims. The each-party-bears-own-costs provision indicates no prevailing party fee award was sought or granted, which is typical of negotiated resolutions. No financial or licensing terms are disclosed in the public record.
US7980998B2 — wearable multi-sensor biosignal monitoring technology
US7980998B2 (application number US12/382214) covers wearable technology directed to multi-sensor biosignal monitoring — the type of physiological parameter detection integrated into sport and health-focused wearable devices. The application date context places the patent’s priority in an era when wearable health monitoring was transitioning from clinical devices to consumer electronics, giving the patent potentially broad claim scope over modern implementations in GPS sport watches.
For the wearable technology sector, US7980998B2 represents a potentially significant enforcement asset. Casio’s G-SHOCK GBDH2000 series — marketed as a 6-sensor GPS multi-sport watch — falls squarely within the product categories most likely to overlap with biosensor patent claims. Any competitor developing smartwatches, fitness trackers, or multi-sport GPS devices incorporating optical heart rate, SpO2, or similar biosensing technology should treat this patent as a material IP risk requiring active monitoring and FTO clearance.
Should your wearable device team run an FTO against US7980998B2?
If your organisation develops or commercialises multi-sport GPS watches, fitness wearables, or any device incorporating biometric sensors — heart rate, SpO2, motion, or similar physiological parameters — US7980998B2 warrants direct FTO review. CardiacSense’s willingness to assert this patent against a major brand like Casio, and Casio’s decision to resolve quickly, suggests the patent may carry genuine claim coverage over commercially deployed wearable biosensor architectures.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US7980998B2 against your product specifications, identify prior art that may support invalidity arguments, and surface related family members or continuation patents that could extend the risk perimeter. Use Eureka to benchmark CardiacSense’s full portfolio and understand whether additional patents could be deployed against similar products in future enforcement actions.
Run a freedom-to-operate analysis on US7980998B2 to assess your product’s exposure
Run FTO in Eureka →Similar wearable biosensor patent infringement cases in US District Courts
Explore related patent infringement actions involving wearable health monitoring and biosensor technology litigated in US District Courts, including the District of New Jersey.
What this case signals for the wearable health-monitoring IP landscape
A 46-day dismissal with prejudice in a wearable biosensor case signals active patent monetisation — and a defendant willing to resolve quickly.
CardiacSense is actively monetising US7980998B2 against wearable device makers
Filing against a high-profile brand like Casio’s G-SHOCK line in the District of New Jersey suggests CardiacSense is pursuing a structured enforcement campaign. Companies developing multi-sport watches or wearables with biosensing capabilities should conduct FTO analysis against US7980998B2 and its family before product launch.
Early settlement preserves patent strength — no invalidity ruling was obtained
Because the case closed before any substantive proceedings, US7980998B2 has not been subjected to judicial claim construction or validity review. This means the patent remains at full presumptive validity, and CardiacSense retains enforcement leverage. Competitors cannot rely on this case to argue the patent is weak or narrow.
CARDIACSENSE v CASIO — key questions answered
The case was dismissed with prejudice on 20 October 2025 by joint stipulation under FRCP 41(a)(1)(A)(ii). The parties stated they had reached resolution. Each side agreed to bear its own costs, expenses, and attorneys’ fees. No court ruling on the merits or patent validity was issued.
CardiacSense accused Casio’s G-SHOCK GBDH2000 series, specifically the GBDH2000-1A, GBDH2000-1A9, and GBDH2000-2 variants, as well as Casio’s 6-Sensor+GPS Multi Sport Watches product line. These are GPS-enabled multi-sport watches with integrated biosensing capabilities.
Dismissal with prejudice operates as a final adjudication on the merits. CardiacSense is permanently barred from refiling the same infringement claims against Casio under US7980998B2. However, this does not prevent CardiacSense from asserting other patents against Casio, or from asserting US7980998B2 against other defendants.
No. The case resolved before any claim construction, Markman hearing, or validity proceedings. US7980998B2 was not subjected to judicial scrutiny in this action and retains its full presumptive validity under 35 U.S.C. § 282. The patent’s enforceability scope remains unresolved from a public-record standpoint.
The public record does not disclose the specific terms or timeline of negotiations. However, a 46-day resolution is consistent with a pre-litigation or very early-stage settlement, potentially involving a licence or lump-sum payment. The joint stipulation language — ‘the parties have reached resolution’ — suggests a mutually agreed commercial outcome rather than unilateral abandonment by either side.
PatSnap Eureka searches patents and litigation data to answer instantly.